SG Americas Securities LLC Acquires 2,077 Shares of Enovis Corporation (NYSE:ENOV)

SG Americas Securities LLC increased its stake in Enovis Corporation (NYSE:ENOV) by 12.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,338 shares of the company’s stock after buying an additional 2,077 shares during the quarter. SG Americas Securities LLC’s holdings in Enovis were worth $739,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ENOV. Farther Finance Advisors LLC increased its position in Enovis by 266.7% during the 1st quarter. Farther Finance Advisors LLC now owns 737 shares of the company’s stock worth $27,000 after buying an additional 536 shares during the period. Aster Capital Management DIFC Ltd bought a new position in Enovis in the fourth quarter valued at about $29,000. Quadrant Capital Group LLC grew its position in Enovis by 53.0% in the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company’s stock valued at $30,000 after acquiring an additional 239 shares during the last quarter. Quarry LP grew its position in Enovis by 506.1% in the fourth quarter. Quarry LP now owns 897 shares of the company’s stock valued at $39,000 after acquiring an additional 749 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Enovis by 144.8% during the first quarter. GAMMA Investing LLC now owns 1,170 shares of the company’s stock valued at $45,000 after purchasing an additional 692 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Analyst Upgrades and Downgrades

ENOV has been the topic of a number of recent analyst reports. Canaccord Genuity Group cut their price objective on Enovis from $75.00 to $70.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. JMP Securities decreased their price objective on Enovis from $62.00 to $55.00 and set a “market outperform” rating for the company in a report on Friday, May 9th. Finally, Needham & Company LLC decreased their price target on Enovis from $64.00 to $57.00 and set a “buy” rating for the company in a report on Friday, May 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $58.00.

Enovis Stock Performance

Shares of ENOV opened at $30.13 on Friday. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -2.16 and a beta of 1.71. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.32 and a current ratio of 2.55. The stock’s 50-day simple moving average is $33.07 and its 200 day simple moving average is $38.98. Enovis Corporation has a 52-week low of $29.13 and a 52-week high of $49.83.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, May 8th. The company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.07. The business had revenue of $558.83 million for the quarter, compared to analyst estimates of $558.80 million. Enovis had a positive return on equity of 5.99% and a negative net margin of 37.65%. The company’s quarterly revenue was up 8.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.50 EPS. Research analysts forecast that Enovis Corporation will post 2.79 EPS for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.